We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. Ilixadencel is currently in a Phase 2 controlled study in renal cell carcinoma (kidney cancer), has completed Phase 1/2 studies in kidney cancer and liver cancer, and has initiated a Phase 1b/2 combination study with checkpoint inhibitors in Head and Neck (HNSCC), Lung (NSCLC) and gastric cancer by the end of 2018. Immunicum is a public company at the Nasdaq Stockholm and has recently raised USD 39 million.